Short Report: Primaquine-Tolerant Plasmodium vivax in an Italian Traveler from Guatemala

Liana Signorini Clinic of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy

Search for other papers by Liana Signorini in
Current site
Google Scholar
PubMed
Close
,
Alberto Matteelli Clinic of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy

Search for other papers by Alberto Matteelli in
Current site
Google Scholar
PubMed
Close
,
Filippo Castelnuovo Clinic of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy

Search for other papers by Filippo Castelnuovo in
Current site
Google Scholar
PubMed
Close
,
Francesco Castelli Clinic of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy

Search for other papers by Francesco Castelli in
Current site
Google Scholar
PubMed
Close
,
Oladayo Oladeji Clinic of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy

Search for other papers by Oladayo Oladeji in
Current site
Google Scholar
PubMed
Close
, and
Glampiero Carosi Clinic of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy

Search for other papers by Glampiero Carosi in
Current site
Google Scholar
PubMed
Close
Restricted access

Plasmodium vivax infections caused by strains with low sensitivity to primaquine are widespread in the Western Pacific and Southeast Asia, and have been recently reported from Central America as well. We report a case of primaquine failure in a P. vivax infection acquired in Guatemala. A 28-year-old Italian woman developed two months after returning from Guatemala a vivax malaria attack that was treated with a standard chloroquine course (1,500 mg over three days) combined with primaquine (15 mg/day for 14 days). Two months later, she had a relapse that was again treated with chloroquine and primaquine at the same doses. After two more months, a second relapse occurred: this time primaquine (30 mg/day for 14 days was administered; the patient remained well during a follow-up period of six months and all parasitologic examination results were negative. Doses of primaquine as high as 6 mg/kg total dose may be indicated in the treatment of vivax malaria cases from Central America.

Author Notes

Past two years Past Year Past 30 Days
Abstract Views 468 231 54
Full Text Views 21 7 3
PDF Downloads 22 9 3
 

 

 

 
 
Affiliate Membership Banner
 
 
Research for Health Information Banner
 
 
CLOCKSS
 
 
 
Society Publishers Coalition Banner
Save